knowledge -WSS

knowledge

author：leisure time 2025-09-03 03:30:53 - browse：85687

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Mayo Clinic plans $5B tech

Wikipedia

WSS

ReNAgade cuts staff seven months after raising $300 million

Fetal surgery at risk from Dobbs and new abortion restrictions

Hospitals need to get ahead of regulations on climate change

Mayo Clinic plans $5B tech

Fetal surgery at risk from Dobbs and new abortion restrictions

Diagnostic tests are hitting their mathematical limits

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Pharma’s losing bet in New Jersey

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pediatric cancer treatments threatened by a new FDA policy

Medicare details structure of new drug price negotiation program

Mayo Clinic plans $5B tech

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ReNAgade cuts staff seven months after raising $300 million

Bright Health sells Medicare Advantage business to Molina

U.K. Biobank has 500,000 peoples' genome sequences available

leisure time

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Louisiana bill approved classifying abortion pills as controlled substances

Hospitals need to get ahead of regulations on climate change

The Bio Revolution is changing business and society

Stroke rates rising, especially in working

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

focus

hotspot

Wikipedia

explore